The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size, Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User, and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    November 2021

  • Pages
    265

  • View Count
    616

Example Insights

Nanoparticle-Contract-Manufacturing-Market-Context Nanoparticle-Contract-Manufacturing-Market-List-of-Nanoparticle-Contract-Manufacturers Nanoparticle-Contract-Manufacturing-Market-Distribution-by-Type-of-Nanoparticle
Nanoparticle-Contract-Manufacturing-Market-Key-Insights Nanoparticle-Contract-Manufacturing-Market-Competitiveness-Analysis Nanoparticle-Contract-Manufacturing-Market-Nanoparticle-based-Therapeutics-Developers
Nanoparticle-Contract-Manufacturing-Market-Partnerships-and-Collaborations Nanoparticle-Contract-Manufacturing-Market-Likely-Growth-Scenarios Nanoparticle-Contract-Manufacturing-Market-Distribution-by-Region

Overview

Majority of big pharma players that offer a wide range off the shelf products and custom services associated with nanoparticles are headquartered in the US. Further, given the rising interest of developer companies to avail contract manufacturing services, such service providers are likely to witness lucrative market opportunities in the foreseen future

-CEO, Europe based Small Sized Company

Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility / permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility.Therefore, players engaged in this domain are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid / metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability / biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles), lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers. 

There are numerous benefits of engaging contract development and manufacturing (CDMO) / contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles). However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in this field, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable growth within the specialty contract manufacturing market in the coming years.

Scope of the Report

The “Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA),  Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed overview  of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial), type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users), type of service(s) offered, quality certifications and regulatory bodies. 
  • An in-depth analysis, highlighting  the contemporary market trends using six schematic representations, including [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain,  [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
  • An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company’s service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).
  • Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • An analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements), type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
  • An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the nanoparticle contract manufacturing market over the next fourteen years. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).  In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players involved in nanoparticle contract manufacturing?
  • Which global regions are considered as key hubs for contract manufacturing of nanoparticles?
  • What are the most common services offered by nanoparticle contract manufacturers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • Which factors are likely to influence the decision of nanoparticle manufacturing being done in-house or outsourced?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of the nanoparticle contract manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction on nanoparticles, along with information on various types and applications of nanoparticles in the pharmaceutical industry. Additionally, it includes information on the various challenges associated with manufacturing of nanoparticles. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of nanoparticle contract manufacturing landscape. It includes information of over 50 contract manufacturers currently engaged in the domain of nanoparticle contract manufacturing. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters (region-wise), type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of nanoparticle manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of end user (educational institutions, pharmaceutical companies, research institutions and other end users), quality certifications, regulatory organizations and include details on type of services offered (analytical method development, fill / finish and packaging, formulation development, manufacturing, method qualification and sustainability, process development / pre-formulation, scale-up, stability studies, and other services).

Chapter 5 highlights the contemporary market trends in six schematic representations, which include [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain,  [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of services offered,), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and types of service(s) offered).

Chapter 6 features a detailed company competitiveness analysis of the nanoparticle contract manufacturers, of very small, small, mid-sized and large companies, based on several relevant parameters, such as company’s service strength (taking into consideration a number of parameters, such as years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and  types of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).

Chapter 7 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the nanoparticle contract manufacturing market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, as well as an informed future outlook.

Chapter 8 features an analysis of recent collaborations and partnerships that have been inked between several stakeholders engaged in this domain, during the period 2015-2021. It includes a brief description of the partnership models (including company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements) adopted by various stakeholders in the domain of nanoparticle contract manufacturing. Further, it comprises of analysis based on the year of partnership, type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement. Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 9 presents an insightful analysis that highlights the various factors that need to be taken into consideration by nanoparticle-based therapeutics developers, while deciding whether to manufacture their respective therapeutics in-house or engage the services of a CMOs. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of the nanoparticle contract manufacturing market, for the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).

Chapter 11 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of nanoparticle contract manufacturing. In this chapter, we have presented the details of our conversation with Asha Van Rooijen and Bart Metselaar (Founder and Chief Executive Officer, Director, Research and Development, LIPOSOMA).

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.2.1. Type of Nanoparticle(s)

3.3. Challenges Associated with Manufacturing of Nanoparticles
3.4 Overview of Contract Manufacturing
3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations

3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
3.6. Key Considerations while Selecting a Contract Manufacturing Partner
3.7. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Organization
4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of End User
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Quality Certifications
4.2.11. Analysis by Regulatory Bodies
4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Company Size and Type of Organization
5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
5.4. Analysis by Company Size and Scale of Operation
5.5. Analysis by Location of Headquarters (Country-wise)
5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, Type of Service(s) Offered (Grid Representation)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Service Strength
6.5. Benchmarking of Partnership Activity
6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
6.6.1. Company Competitiveness Analysis: Very Small Companies
6.6.2. Company Competitiveness Analysis: Small Companies
6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Curia
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Corden Pharma
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Evonik
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. LSNE Contract Manufacturing
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

7.7. Polymun
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook

7.8. TechNanoIndia
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
8.3.5. Emerging Focus Areas
8.3.6. Analysis by Seniority Level of Stakeholders
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. Region-wise Distribution
8.3.8.2. Country-wise Distribution

9. OUTSOURCING: GO / NO-GO FRAMEWORK
9.1. Chapter Overview
9.2. Assumptions and Parameter Definitions
9.3. Nanoparticle-based Therapeutics Developers Outsourcing: Go / No-Go Framework
9.3.1. Scenario 1
9.3.2. Scenario 2
9.3.3. Scenario 3
9.3.4. Scenario 4
9.3.5. Scenario 5

9.4. Outsourcing: Go / No-Go Framework
9.4.1. Very Small Companies
9.4.2. Small Companies
9.4.3. Mid-Sized Companies
9.4.4. Large Companies

9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035
10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035

10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035
10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035

10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035
10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035
10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035

10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035
10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
10.7.4. Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035

10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
10.8.4. Nanoparticle Contract Manufacturing Market in MENA, 2021-2035
10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035

10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035
10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA,2021-2035
10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. LIPOSOMA
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Application of Nanoparticles in Healthcare
Figure 3.2 Type of Nanoparticle(s) Based on Source of Material
Figure 3.3 Challenges Associated with Manufacturing of Nanoparticles
Figure 3.4 Type of the Third- Party Service Provider(s)
Figure 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
Figure 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
Figure 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Figure 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Figure 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Figure 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Figure 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Figure 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Figure 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-wise) and Type of Nanoparticle(s) Manufactured
Figure 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Figure 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Figure 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Figure 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Figure 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Figure 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End User
Figure 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
Figure 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
Figure 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Figure 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Figure 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Figure 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Figure 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Figure 5.1 Key Insights: Distribution by Company Size and Type of Organization
Figure 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Figure 5.3 Key Insights: Distribution by Company Size and Scale of Operation
Figure 5.4 Key Insights: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
Figure 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
Figure 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
Figure 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Figure 8.7 Partnerships and Collaborations: Emerging Focus Area
Figure 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
Figure 8.9 Most Active Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: Distribution by Geography
Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Outsourcing: Go / No-Go Framework
Figure 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
Figure 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (USD Billion)
Figure 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Figure 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (USD Billion)
Figure 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (USD Billion)
Figure 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (USD Billion)
Figure 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (USD Billion)
Figure 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Figure 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (USD Billion)
Figure 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (USD Billion)
Figure 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Figure 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (USD Billion)
Figure 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (USD Billion)
Figure 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (USD Billion)
Figure 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
Figure 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (USD Billion)
Figure 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (USD Billion)
Figure 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (USD Billion)
Figure 10.18 Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 (USD Billion)
Figure 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Figure 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (USD Billion)
Figure 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (USD Billion)
Figure 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (USD Billion)
Figure 10.23 Nanoparticle Contract Manufacturing Market in MENA, 2021-2035 (USD Billion)
Figure 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (USD Billion)
Figure 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (USD Billion)
Figure 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
Figure 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (USD Billion)
Figure 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (USD Billion)
Figure 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (USD Billion)
Figure 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035 (USD Billion)
Figure 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (USD Billion)
Figure 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
Figure 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (USD Billion)
Figure 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (USD Billion)
Figure 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (USD Billion)
Figure 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035 (USD Billion)
Figure 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (USD Billion)
Figure 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
Figure 12.1 Concluding Remarks: Market Landscape
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Application of Nanoparticles in Healthcare
Table 3.2 Type of Nanoparticle(s) Based on Source of Material
Table 3.3 Challenges Associated with Manufacturing of Nanoparticles
Table 3.4 Type of the Third- Party Service Provider(s)
Table 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
Table 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
Table 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Table 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Table 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Table 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Table 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Table 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Table 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-wise) and Type of Nanoparticle(s) Manufactured
Table 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Table 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Table 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
Table 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Table 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Table 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Table 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End User
Table 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
Table 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
Table 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Table 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Table 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Table 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Table 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Table 5.1 Key Insights: Distribution by Company Size and Type of Organization
Table 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Table 5.3 Key Insights: Distribution by Company Size and Scale of Operation
Table 5.4 Key Insights: Distribution by Location of Headquarters (Country-wise)
Table 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
Table 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
Table 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
Table 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
Table 6.3 Company Competitiveness Analysis: Very Small Companies
Table 6.4 Company Competitiveness Analysis: Small Companies
Table 6.5 Company Competitiveness Analysis: Mid-sized Companies
Table 6.6 Company Competitiveness Analysis: Large Companies
Table 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Table 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Table 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Table 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Table 8.7 Partnerships and Collaborations: Emerging Focus Area
Table 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
Table 8.9 Most Active Players: Distribution by Number of Partnerships
Table 8.10 Partnerships and Collaborations: Distribution by Geography
Table 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 9.1 Outsourcing: Go / No-Go Framework
Table 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
Table 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (USD Billion)
Table 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Table 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (USD Billion)
Table 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (USD Billion)
Table 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (USD Billion)
Table 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (USD Billion)
Table 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Table 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (USD Billion)
Table 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (USD Billion)
Table 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Table 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (USD Billion)
Table 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (USD Billion)
Table 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (USD Billion)
Table 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
Table 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (USD Billion)
Table 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (USD Billion)
Table 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (USD Billion)
Table 10.18 Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 (USD Billion)
Table 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Table 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (USD Billion)
Table 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (USD Billion)
Table 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (USD Billion)
Table 10.23 Nanoparticle Contract Manufacturing Market in MENA, 2021-2035 (USD Billion)
Table 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (USD Billion)
Table 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (USD Billion)
Table 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
Table 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (USD Billion)
Table 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (USD Billion)
Table 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (USD Billion)
Table 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035 (USD Billion)
Table 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (USD Billion)
Table 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
Table 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (USD Billion)
Table 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (USD Billion)
Table 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (USD Billion)
Table 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035 (USD Billion)
Table 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (USD Billion)
Table 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
Table 12.1 Concluding Remarks: Market Landscape
Table 12.2 Concluding Remarks: Partnerships and Collaborations
Table 12.3 Concluding Remarks: Market Forecast

List Of Companies

  1. Ajinomoto Bio-Pharma Services
  2. Alfa Aesar
  3. Amplicon Biotech
  4. Applied Chemical Works
  5. Arcturus Therapeutics
  6. Ardena
  7. Ascendia Pharmaceuticals
  8. AstraZeneca
  9. AVANSA Technology & Services
  10. Avanti Polar Lipids
  11. Axolabs
  12. BASF
  13. BBI Group
  14. BioNTech
  15. BIOZOL Diagnostica
  16. BOC Sciences
  17. Caisson Biotech
  18. Cal Nano
  19. Cambridge Nanomaterials Technology
  20. CanSinoBIO
  21. Cayman Chemical
  22. CONTRACTOR BUSINESS CENTER
  23. Celonic
  24. Center for Applied Nanotechnology
  25. Cerion
  26. ChemConnection 
  27. CliniSciences
  28. CordenPharma
  29. Creative Biolabs
  30. Croda
  31. Crystallics
  32. CureVac
  33. Curia
  34. CYBERNANO
  35. Cytodiagnostics 
  36. Daiichi Sankyo
  37. Danaher
  38. DCN Dx
  39. Deakin University
  40. Dolomite Microfluidics
  41. E.M. Sullivan Associates
  42. Eikonix
  43. EMJapan
  44. Encapsula NanoSciences
  45. Entos
  46. European Commission
  47. Evonik
  48. Exelead
  49. Fortis Life Sciences
  50. FUJIFILM Holdings 
  51. GHO Capital
  52. Howei Pharm
  53. Hongwu International Group
  54. i-DNA Biotechnology
  55. Idifarma
  56. Integrity Bio
  57. Larodan
  58. LEON
  59. LIPOSOMA
  60. LSNE Contract Manufacturing
  61. Meliorum Technologies
  62. Molchem Technologies UK
  63. MyBiotech
  64. Nagase Medicals
  65. Nanochemazone
  66. nanoComposix
  67. Nanocs
  68. NanoHybrids
  69. NanoMaterials Technology
  70. Nanomics Technologies 
  71. Nanophase Technologies
  72. Nanoshel
  73. Nanostructured & Amorphous Materials
  74. NARD Institute
  75. NNCrystal
  76. Novo Holdings
  77. Nucleus Medical Media
  78. NVIGEN
  79. NYACOL® Nano Technologies
  80. Ocean NanoTech
  81. Osaka University
  82. Permira
  83. Pfizer
  84. Pharmavize
  85. Phosphorex
  86. Polymun
  87. Precision NanoSystems
  88. Pró-Análise 
  89. Prodotti Gianni
  90. Santhiram Chemicals
  91. Seashell Technology
  92. Shionogi
  93. Sirnaomics
  94. SkySpring Nanomaterials
  95. Stanipharm
  96. Stratech Scientific
  97. Strem 
  98. Syntagon
  99. T&T Scientific
  100. TechNanoIndia
  101. The Energy and Resources Institute (TERI)
  102. U.S. Army
  103. Vaxinano
  104. Veritas Technologies
  105. ZoneOne Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com